A risk calculator predicting recurrence in lymph node metastatic penile cancer
| Autor: | Oliver W. Hakenberg, Yao Zhu, Alberto Briganti, Filippo Pederzoli, Dingwei Ye, Hielke M. de Vries, Axel Heidenreich, Mohamed E. Ahmed, Maarten Albersen, Juan Chipollini, Roberto Salvioni, Mario Catanzaro, Antonio Augusto Ornellas, Laura Marandino, Jeffrey Karnes, Philippe E. Spiess, Eduard Roussel, Andrea Necchi, Francesco Montorsi, Oscar R. Brouwer, Nick Watkin, Marco Bandini, Mounsif Azizi, Friederike Haidl, Michael Ager |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Referral Proportional hazards model business.industry Urology medicine.medical_treatment 030232 urology & nephrology medicine.disease 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Internal medicine Cohort medicine Penile cancer Radiation treatment planning business Lymph node Adjuvant Metastatic Penile Cancer |
| Zdroj: | BJU International. 126:577-585 |
| ISSN: | 1464-4096 |
| Popis: | Objectives To develop and externally validate a risk calculator for prediction of any cancer recurrence in patients with penile squamous cell carcinoma (pSCC) and inguinal lymph node metastases (ILNM), as to date no validated prognostic tool is available for patients with pSCC and ILNM. Patients and methods The development cohort included 234 patients from seven referral centres. The external validation cohort included 273 patients from two additional referral centres. Cox regression identified predictors of any recurrence, which were used to develop a risk calculator. The risk-calculator grouped the development and the validation cohorts according to the individual risk of any recurrence at 24 months (24m-R). Adjuvant treatment effects were tested on overall survival (OS) according to the derived tertiles, within the development and validation cohorts. Results Positive surgical margins, pN3 , and ILNM ratio were associated with higher recurrence rate. The 2-year OS rates were lower for patients with high (>37%) and intermediate (19-37%) compared to low ( 0.1). Conclusion Adjuvant treatment planning is crucial in patients with pSCC with ILNM, where only weak evidence is available. The current tool proved to successfully stratify patients according to their individual risk, potentially allowing better tailoring of adjuvant treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text